Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
Progression-Free Survival (PFS) | REVLIMID® (lenalidomide) + rituximab
REVEL Trial Progression-Free Survival for mNSCLC | CYRAMZA® (ramucirumab)
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small
Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
Kaplan-Meier curve of median progression-free survival (PFS) and... | Download Scientific Diagram
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan-Meier curves of progression-free survival (PFS) and overall... | Download Scientific Diagram
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
